HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02435901|
Recruitment Status : Completed
First Posted : May 6, 2015
Results First Posted : November 5, 2020
Last Update Posted : August 24, 2021
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Disease Beta Thalassemia-Major||Drug: alemtuzumab (Campath IH) Drug: Fludarabine Drug: Melphalan Drug: Cyclosporine Drug: Mycophenolate mofetil Drug: Tacrolimus Biological: Hematopoietic Stem Cell Transplantation||Phase 1 Phase 2|
Standard myeloablative regimens are toxic to non-hematopoietic tissue and are associated with treatment related mortality and morbidity (TRM). Preparative regimens that are not myeloablative are associated with a greatly decreased incidence of TRM. In addition to providing a less toxic regimen, the reduced intensity chemotherapy preparative regimen also remains immunosuppressive enough to allow donor engraftment. Recent report of non-myeloablative regimens which resulted in engraftment of allogeneic stem cell in hematological malignancies raises the possibility that this conditioning regimen might be useful in achieving engraftment in non hematological disorder.
In an effort to achieve stable engraftment with any suitable donor stem cell source and to minimize toxicity the investigators have developed a new reduced intensity conditioning regimen for high risk hemoglobinopathies with the main aim of significantly suppressing the recipient's immune system and facilitate engraftment.
Non-myeloablative or reduced-intensity immunosuppressive preparative regimens have achieved a stable, mixed chimerism engraftment and successful allogeneic bone marrow transplants.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||29 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH RISK HEMOGLOBINOPATHIES LIKE SICKLE CELL DISEASE AND β-THALESSEMIA-MAJOR USING REDUCED INTENSITY CONDITIONING REGIMEN|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||March 2019|
|Actual Study Completion Date :||December 2019|
Experimental: Reduced Intensity Regimen
Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients <10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients > 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.
Drug: alemtuzumab (Campath IH)
Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
Other Name: Campath-IH
Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
Drug: Mycophenolate mofetil
Immunosuppressant to prevent graft vs host disease is given on Day -1.
Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
Biological: Hematopoietic Stem Cell Transplantation
Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
- Number of Participants With Sustained Cell Engraftment of Donor Cells [ Time Frame: 1 year ]Sustained stem cell engraftment of donor cells will be evaluated by chimerism (FISH fluorescence in situ hybridization OR VNTR (Variable Number of Tandem Repeats), based on recipient/donor gender, at 30 days, 100 days, 6 months and 1 year following the use of reduced intensity conditioning.
- Assessment of Treatment Related Mortality and Morbidity [ Time Frame: 2 years ]Patients will be evaluated for incidence and severity of graft versus host disease, infection, and cardiopulmonary complications.
- Event Free Survival; Number of Participants Who Survived at 2 Years [ Time Frame: 2 years ]29 participants will be evaluated for Event Free Survival.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||1 Year to 21 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patient Inclusion Criteria for Sickle Cell Disease
- Patients at least one year of age to less than or equal to 21 years of age with (Sickle Cell Disease-SS or Sickle Cell-S-β-Thalassemia and with one or more of the following disease complications:
- Development of stroke on chronic transfusion protocol.
- Allosensitization on chronic transfusion therapy
- Impaired neuropsychological function and abnormal MRI scan
- Abnormal Transcranial Doppler studies
- Acute chest syndrome (2 to 3 episodes of acute chest syndrome in last 3 to 4 years).
- Ferritin level < 1500 mg/ml
- Recurrent painful priapism; 3-4 episodes/year requiring intervention.
- Recurrent vaso-occlusive crisis of at least 3 to 4 episodes/year.
- Osteonecrosis of multiple bones with documented destructive changes.
- Signed informed consent
- Patients physically and psychologically capable of undergoing transplantation and a period of strict isolation.
- Ferritin < 1500
- Liver Iron Concentration < 6mg/g
Patient Inclusion Criteria for β Thalassemia major Patients less than or equal to 21 years of age with B- Thalassemia major on routine monthly transfusion protocol or with one or more of the following complications;
- Liver biopsy revealing evidence of portal fibrosis as A) Mild B) Moderate
- Ferritin level≤ 1500ng/ml
- Liver Iron Concentration (LIC) < 6mg/g
- Exclusion Criteria for Both Sickle Cell and β Thalassemia Major Patient
- HIV positive result confirmed by Western Blot.
- Pregnancy (Pregnancy testing for females of child-bearing age will be performed and those with a positive serum β-Human Chorionic Gonadotropin will be excluded) and lactating females.
- Creatinine greater than two times the upper limit of normal for the laboratory,
- Pulmonary disease with FVC, FEV1 or DLCO parameters < 50% predicted (corrected for hemoglobin) or stage 3 or 4 sickle lung disease.
- Cardiac insufficiency or coronary artery disease requiring treatment
- Active infection requiring systemic antibiotic therapy with antibacterial, antifungal or antiviral agents
- Lansky performance score <70%- (Appendix B)
- Acute hepatitis/biopsy evidence of cirrhosis.
- Pulmonary Hypertension
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02435901
|United States, New York|
|Cohen Children's Medical Center of New York|
|New Hyde Park, New York, United States, 11040|
Documents provided by Northwell Health:
|Responsible Party:||Northwell Health|
|Other Study ID Numbers:||
|First Posted:||May 6, 2015 Key Record Dates|
|Results First Posted:||November 5, 2020|
|Last Update Posted:||August 24, 2021|
|Last Verified:||July 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Outcome data to include study findings.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Reduced Intensity Conditioning Regimen
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs